Jan 31 (Reuters) - Medical equipment maker Revvity ( RVTY )

forecast full-year profit and revenue for 2025 below

Wall Street estimates on Friday, as it expects soft demand for

its products and services used in drug research.

The company has faced challenges from reduced spending from

biotech clients and smaller drug developers amid

higher-for-longer interest rates.

The diagnostic products and scientific tools manufacturer

forecast 2025 adjusted profit to be in the range of $4.90 to

$5.00 per share, the mid-point of which is below analysts'

estimates of $4.99, as per data compiled by LSEG.

Revvity ( RVTY ) expects 2025 revenue to be in the range of $2.80

billion to $2.85 billion, compared with estimates of $2.87

billion.

The company, however, beat fourth-quarter profit and revenue

estimates, on the back of strong sales in its life sciences and

diagnostics units.

On an adjusted basis, Revvity ( RVTY ) earned a profit of $1.42 per

share, topping analysts' estimates of $1.37.

The Massachusetts-based company reported fourth-quarter

revenue of $729.4 million, compared with estimates of $727.9

million.

The company's life sciences unit, which provides reagents

and instruments for drug discovery, brought in revenue of $336.3

million during the quarter, compared with estimates of $327.9

million.

Sales in its diagnostic unit, which provides testing tools

for processes such as genetic screening, rose 4% to $393.2

million.

Formerly known as PerkinElmer, the company divested three of

its businesses in 2022 to focus on life sciences and diagnostics

units.